(Total Views: 621)
Posted On: 09/03/2020 10:47:09 AM
Post# of 208
In my opinion It is pertinent to say TSOI is not just pursuing as opportunistic drug development for COVID-19 but is definitely an genuine opportunity as SARS-COV2 is something that occurs in COVID-19 patients and is expected to stay forever with us from now on just like any common viruses.
Even if there is COVID-19 vaccine gets developed in the meantime, it certainly does not mean that QM/STEMVACS/JADICELL in treating COVID-19 is not going to go in vain. It has already been reported by TSOI that QM/NS when used with HERCEPTIN/METFORMIN/MINOCYCLINE ( FDA aaproved blockbuster drugs) has been reported to have great synergistic benefits when used with for a completely different indication(s), but the mantra is same in that it reduces inflammation, increases immunity in the process suppresses INTERLEUKIN-1, ORF8/NLRP3, INTERLEUKIN-18, INTERFERON GAMMA cells, furthermore activates NK cells, de-acetylates NLRP3 protien.
It is fantastic that TSOI has valid reason for repositioning QM, NS, STEMVACS and JADICELL to treat COVID-19.
It is definitely expected that TSOI will aim to have partnerships with multiple BIG PHARMA COMPANIES , because the population that its product(s) QM/STEMVACS/JADICELL/NANO STILBENE is/are targeting is very of high mortality rate.
Even if there is COVID-19 vaccine gets developed in the meantime, it certainly does not mean that QM/STEMVACS/JADICELL in treating COVID-19 is not going to go in vain. It has already been reported by TSOI that QM/NS when used with HERCEPTIN/METFORMIN/MINOCYCLINE ( FDA aaproved blockbuster drugs) has been reported to have great synergistic benefits when used with for a completely different indication(s), but the mantra is same in that it reduces inflammation, increases immunity in the process suppresses INTERLEUKIN-1, ORF8/NLRP3, INTERLEUKIN-18, INTERFERON GAMMA cells, furthermore activates NK cells, de-acetylates NLRP3 protien.
It is fantastic that TSOI has valid reason for repositioning QM, NS, STEMVACS and JADICELL to treat COVID-19.
It is definitely expected that TSOI will aim to have partnerships with multiple BIG PHARMA COMPANIES , because the population that its product(s) QM/STEMVACS/JADICELL/NANO STILBENE is/are targeting is very of high mortality rate.
(0)
(0)Scroll down for more posts ▼
